| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40262-019-00822-9 |
| P698 | PubMed publication ID | 31583609 |
| P50 | author | Felix Stader | Q90473690 |
| Melissa A. Penny | Q42305846 | ||
| P2093 | author name string | Manuel Battegay | |
| Catia Marzolini | |||
| Marco Siccardi | |||
| Hannah Kinvig | |||
| P2860 | cites work | Estimating the mean and variance from the median, range, and the size of a sample | Q24801782 |
| Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers | Q28365919 | ||
| Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals | Q30828459 | ||
| A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance | Q33532744 | ||
| Clinical pharmacokinetics of clarithromycin | Q33789227 | ||
| Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation | Q34389546 | ||
| Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat | Q34447399 | ||
| The effect of age on the pharmacokinetics of metoprolol and its metabolites | Q34448597 | ||
| The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. | Q51452482 | ||
| Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. | Q51572625 | ||
| Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. | Q51759761 | ||
| Effect of age, gender, and obesity on midazolam kinetics. | Q51841259 | ||
| Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. | Q52312048 | ||
| Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions | Q57684574 | ||
| Blood level of cimetidine in relation to age | Q66923470 | ||
| Aging and ethanol metabolism | Q67548911 | ||
| Pharmacokinetics of cefixime in the young and elderly | Q68488346 | ||
| Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics | Q69058202 | ||
| Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients | Q69676772 | ||
| Pharmacokinetics of lisinopril | Q69837908 | ||
| Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure | Q69912198 | ||
| Imipramine and desipramine disposition in the elderly | Q70045130 | ||
| Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks | Q70665715 | ||
| Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals | Q71705871 | ||
| Aging and physiological changes of the kidneys including changes in glomerular filtration rate | Q84742627 | ||
| Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions | Q89367491 | ||
| Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes | Q91056450 | ||
| Physiologically based pharmacokinetic modelling to guide drug delivery in older people | Q91317659 | ||
| A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab® | Q91699200 | ||
| Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects | Q94705893 | ||
| Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor | Q34455896 | ||
| Repaglinide pharmacokinetics in healthy young adult and elderly subjects | Q34503808 | ||
| Plasma metoprolol concentrations in young, old and hypertensive subjects | Q34515719 | ||
| The effect of ageing on the hepatic clearance of propranolol | Q34517399 | ||
| Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability | Q34574831 | ||
| Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir | Q35002453 | ||
| Clinical Pharmacokinetics of Atorvastatin | Q35553211 | ||
| The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes | Q35886027 | ||
| Predicted metabolic drug clearance with increasing adult age. | Q36729942 | ||
| Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model | Q36947718 | ||
| Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 | Q37126489 | ||
| Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis | Q37279044 | ||
| Statin therapy in the elderly: a review | Q37393348 | ||
| A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn | Q37404434 | ||
| A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine | Q37470663 | ||
| Modeling and predicting drug pharmacokinetics in patients with renal impairment. | Q37960638 | ||
| Pharmacotherapy considerations in elderly adults | Q38032114 | ||
| Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach | Q38087695 | ||
| The clinical pharmacology of lisinopril | Q38178569 | ||
| Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range | Q38294119 | ||
| Effects of cardiovascular disease on pharmacokinetics | Q38378935 | ||
| Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide | Q39212609 | ||
| Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes | Q39418438 | ||
| Clinical Pharmacokinetics of Rifampicin | Q39720647 | ||
| Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds | Q40100581 | ||
| Sex differences in pharmacokinetics and pharmacodynamics | Q40398634 | ||
| Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites | Q40791912 | ||
| Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction | Q41188364 | ||
| Digoxin in the elderly: Pharmacokinetic consequences of old age | Q41617375 | ||
| Effects of age and cigarette smoking on propranolol disposition | Q41617556 | ||
| The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily | Q41855699 | ||
| Enalapril maleate and a lysine analogue (MK-521): disposition in man | Q42264743 | ||
| Pharmacokinetic and Antihypertensive Profile of Amlodipine and Felodipine-ER in Younger Versus Older Patients With Hypertension | Q42873343 | ||
| The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor | Q43970129 | ||
| An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection | Q44999068 | ||
| Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects | Q46194222 | ||
| Age-Related Diseases and Clinical and Public Health Implications for the 85 Years Old and Over Population | Q47563529 | ||
| Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model | Q50050263 | ||
| Medication for older people--aspects of rational therapy from the general practitioner's point of view. | Q50472346 | ||
| Effect of age and gender on pharmacokinetics of atorvastatin in humans. | Q51025197 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 383-401 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly | |
| P478 | volume | 59 |
| Q98284637 | Clinical data combined with modelling and simulation indicate unchanged drug-drug interaction magnitudes in the elderly | cites work | P2860 |
Search more.